The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity

Klimczak, Katarzyna; Łykowska‐Szuber, Liliana; Eder, Piotr; Krela‐Kaźmierczak, Iwona; Stawczyk‐Eder, Kamila; Szymczak, Aleksandra; Michalak, Michał; Studniarek, Adam; Linke, Krzysztof

doi:10.1016/j.ejim.2015.06.015

Cited by 9 publications

(8 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…On this basis, the short-, medium-and long-term targets were defined for CD treatment. These are discussed in detail in the recommendations regarding the induction and maintenance treatment [67][68][69][70][71].…”

Section: Optimal Assessment Ofmentioning

confidence: 99%

Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

Łodyga¹,

Eder²,

Gawron-Kiszka³

et al. 2021

Self Cite

View full text Add to dashboard Cite

This paper is an update of the diagnostic and therapeutic recommendations of the National Consultant for Gastroenterology and the Polish Society of Gastroenterology from 2012. It contains 46 recommendations for the diagnosis and treatment, both pharmacological and surgical, of Crohn's disease in adults. The guidelines were developed by a group of experts appointed by the Polish Society of Gastroenterology and the National Consultant in the field of Gastroenterology. The methodology related to the GRADE methodology was used to assess the quality and strength of the available recommendations. The degree of expert support for the proposed statement, assessment of the quality of evidence and the strength of the recommendation was assessed on a 6-point Likert scale. Voting results, quality and strength ratings with comments are included with each statement.

show abstract

Section: Optimal Assessment Ofmentioning

confidence: 99%

Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

Łodyga¹,

Eder²,

Gawron-Kiszka³

et al. 2021

Self Cite

View full text Add to dashboard Cite

show abstract

“…The usefulness of FL in the prediction of endoscopically active disease in the colon has been recently confirmed in a study on 101 patients, reporting 84.6% sensitivity and 60.5% specificity ( p = 0.0347), with PPV of 42% and NPV of 92% at a concentration of 145.82 μg/mL [42]. A good correlation of FL with endoscopic scores was shown only in 5 out of 15 studies (Table 2) [9, 10, 39, 41, 43].…”

Section: Stool Markers and Endoscopic Activitymentioning

confidence: 97%

Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn’s Disease: Do They Still Have a Potential Clinical Role?

et al. 2021

View full text Add to dashboard Cite

Introduction: The need for noninvasive markers of disease activity is mandatory in the assessment of Crohn’s disease (CD). The most widely fecal biomarker in CD, despite several limits, is fecal calprotectin. This review aims to elucidate the role, if any, of all other fecal biomarkers, as alternative tools for assessing clinical and endoscopic disease activity, and predict capsule endoscopy findings, response to therapy, disease relapse, and postoperative recurrence. These fecal biomarkers included lactoferrin, S100A12, high mobility group box 1, neopterin, polymorphonuclear neutrophil elastase, fecal hemoglobin, alpha1-antitrypsin, lysozyme, human beta-defensin-2, neutrophil gelatinase-associated lipocalin, matrix metalloproteinase-9, chitinase 3-like-1, M2-pyruvate kinase, myeloperoxidase, and eosinophil proteins. Methods: A systematic electronic search in the medical literature was performed up to April 2020. Seventy eligible studies were identified out of 859 citations. Data were grouped according to the assessment of clinical and endoscopic disease activity, capsule endoscopy findings, response to therapy, prediction of relapse, and postoperative recurrence. Results: The overall correlation between lactoferrin and clinical indexes is poor, while performance is good with endoscopic scores. Lactoferrin seems to represent a reasonably good surrogate marker of response to therapy and to be potentially useful in identifying patients at high risk for endoscopic relapse or postoperative recurrence. The evaluation of the performance of all other fecal markers is limited by the lack of adequate data. Conclusions: None of the fecal markers so far represents an acceptable alternative to calprotectin in clinical practice. Fecal lactoferrin is the only possible exception, but a more extensive investigation is still required.

show abstract

“…After screening 5,303 publications, we identified 21 eligible studies 20,28,[31][32][33][34][35][36][37][38][39][40][41][42][43][44][45][46][47][48][49] reporting on 27 diagnostic models for the prediction of ileocolonic endoscopic activity and/or EH in patients with Crohn's disease (Figure 1 and Supplementary Material 3).…”

Section: Systematic Literature Searchmentioning

confidence: 99%

“…Authors from these studies were contacted, and extra information was provided by the authors of four studies 28,34,37,45 representing five models. In total, 20 models could not be externally validated, because: 1) ten models 35,39,40,42,44,48 did not provide sufficient detail to allow external validation, 2) six models 31,34,37,45,46 included investigational biomarkers, 3) four models 33,38,41,49 used predictors not available in the TAILORIX and/or UAI dataset (Supplementary material 12). Nonetheless, seven models 20,28,32,36,41,43,47 could be externally validated: six models in the TAILORIX dataset, and five models in the UAI dataset (obviously, the UAI model was not validated in its own development dataset).…”

Section: Models In-and Excluded For External Validationmentioning

confidence: 99%

Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

Brand

Elias

Minderhoud

et al. 2020

Clinical Gastroenterology and Hepatology

View full text Add to dashboard Cite

Grant supportEelco Brand is supported by the Alexandre Suerman program for MD and PhD candidates of the University Medical Center Utrecht, Netherlands. AbbreviationsAUC, area under the receiver operating characteristic curve CD, Crohn's disease CDAI, Crohn's disease activity index CDEIS, Crohn's disease endoscopic index of severity CHARMS, critical appraisal and data extraction for systematic reviews of prediction modeling studies CI, confidence interval CRP, C-reactive protein EH, endoscopic healing ESR, erythrocyte sedimentation rate HBI, Harvey-Bradshaw Index SESCD, Simple endoscopic score for Crohn's disease TAILORIX, a randomized controlled trial investigating tailored treatment with infliximab for active luminal Crohn's disease TNF-α, tumor necrosis factor-α UAI, Utrecht Activity Index

show abstract

The diagnostic usefulness of fecal lactoferrin in the assessment of Crohn's disease activity

Cited by 9 publications

References 32 publications

Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

Guidelines for the management of patients with Crohn’s disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology

Fecal Lactoferrin and Other Putative Fecal Biomarkers in Crohn’s Disease: Do They Still Have a Potential Clinical Role?

Systematic Review and External Validation of Prediction Models Based on Symptoms and Biomarkers for Identifying Endoscopic Activity in Crohn's Disease

Contact Info

Product

Resources

About